Though things are looking up for Akero, the stock still looks risky. Akero Therapeutics is developing efruxifermin as a ...

Akero Therapeutics is developing efruxifermin as a potential treatment for metabolic dysfunction-associated steatohepatitis (MASH), a non-alcohol-related liver disease. MASH is linked to a ...

Rolph Timothy, the Chief Scientific Officer of Akero Therapeutics Inc . (NASDAQ:AKRO), recently executed a notable share sale ...

We recently compiled a list of the 12 Best Booming Stocks to Invest in Now. In this article, we are going to take a look at ...

We recently compiled a list of the Why These 15 Healthcare Stocks Are Skyrocketing So Far In 2025. In this article, we are ...

Akero Therapeutics Inc (NASDAQ ... drug achieved ≥1 stage improvement in liver fibrosis without worsening of MASH at 96 weeks. This is compared to 15% for placebo. The results were consistent ...

and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients. Receive News & Ratings for Akero Therapeutics Daily - Enter ...

Akero Therapeutics Inc. is a clinical-stage biotechnology company ... a treatment for metabolic dysfunction-associated steatohepatitis, also referred to as MASH. The drug was well-received by ...